A primary purpose of the ICH is to:

The primary purpose of the International Council for Harmonisation (ICH) is indeed to minimize the need for redundant research. This organization was established to promote consistent and efficient drug development by harmonizing regulatory requirements across different countries. By aligning the standards and guidelines for clinical trials and drug registration, the ICH aims to allow researchers to conduct studies in a way that is accepted globally, reducing instances where similar trials are conducted separately in different countries. This harmonization not only saves time and resources but also helps streamline the approval process for new therapies, ultimately benefiting both researchers and patients.

As for the other choices: requiring FDA registration of worldwide clinical trials or the publication of negative trial results are not primary objectives of the ICH. While these topics are important in the context of clinical research, they do not encapsulate the overarching goal of minimizing redundant studies. Additionally, the development of mandatory worldwide regulations for drug development goes beyond the ICH’s mission, which focuses on harmonization rather than imposing strict regulations.